Emily Stevens, MD
Hematology & Oncology · Federal Way, WANPI 1669798195
Payments from drug & device makers
Across 8 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$89
- AstraZeneca$46
- CTI Biopharma Corp.$22
- GSK$21
- Incyte Corporation$18
- Pharmacyclics LLC, An Abbvie Company$16
- plus $12 from 1 others
What the payments were for
- Food & beverage$222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $89 |
| AstraZeneca | 2 | $46 |
| CTI Biopharma Corp. | 1 | $22 |
| GSK | 1 | $21 |
| Incyte Corporation | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$222 in reported general payments places this provider in the 20th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $23,576 |
| Letrozole | 40 | $526 |
| Tamoxifen Citrate | 14 | $335 |
| Hydroxyurea | 11 | $236 |
| Olanzapine | 13 | $185 |
| Ondansetron OdtOndansetron | 14 | $163 |
| Anastrozole | 12 | $160 |
| Gabapentin | 16 | $112 |
| Prochlorperazine Maleate | 12 | $92 |
| Oxycodone Hcl | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Federal Way
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Sibel BlauPuyallup$11.9M
- Arvind ChaudhrySpokane$11.5M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.